粒细胞-巨噬细胞集落刺激因子联合或不联合监督下运动对外周动脉疾病患者步行能力的影响:PROPEL随机临床试验
PROPEL随机临床试验采用2×2析因设计,纳入210例外周动脉疾病患者,比较监督下跑步机运动与宣教对照、以及粒细胞-巨噬细胞集落刺激因子(GM-CSF)与安慰剂对12周随访时6分钟步行距离变化的影响。结果显示,监督下运动较宣教对照显著改善6分钟步行距离,而GM-CSF单用或联合运动均未显著改善步行能力。
要点
- 监督下跑步机运动较宣教对照显著改善6分钟步行距离(平均差+33.6米)。
- GM-CSF单用较安慰剂未显著改善6分钟步行距离(平均差-1.4米)。
- GM-CSF联合运动较单用运动未显著改善6分钟步行距离(平均差-6.3米)。
核心结论
- 在外周动脉疾病患者中,监督下跑步机运动较宣教对照显著改善6分钟步行距离,而GM-CSF单用或联合运动均未显著改善步行能力。
研究设计与样本
- 随机临床试验,2×2析因设计,于2012年1月6日至2016年12月22日在芝加哥大都市区纳入210例外周动脉疾病患者。
- 参与者随机分入4组:监督下运动+GM-CSF组(n=53)、监督下运动+安慰剂组(n=53)、宣教对照+GM-CSF组(n=53)、宣教对照+安慰剂组(n=51)。
- 监督下运动为每周3次跑步机运动,持续6个月;宣教对照为临床医生每周教育讲座,持续6个月。
- GM-CSF(250 μg/m2/d)或安慰剂皮下注射,双盲,干预前2周每周3次。
- 主要结局为12周随访时6分钟步行距离变化,最小临床重要差异为20米。
主要发现
- 共评估827人,随机化210例外周动脉疾病患者(平均年龄67.0岁[SD 8.6];141例[67%]黑人,82例[39%]女性);195例(93%)完成12周随访。
- 12周随访时,运动+GM-CSF组较单用运动组6分钟步行距离未显著改善(平均差-6.3米[95%CI -30.2至+17.6];P=.61)。
- 运动+GM-CSF组较单用GM-CSF组6分钟步行距离平均差+28.7米(95%CI +5.1至+52.3;Hochberg校正P=.052)。
- 单用GM-CSF组较宣教对照+安慰剂组6分钟步行距离未显著改善(平均差-1.4米[95%CI -25.2至+22.4];P=.91)。
- 单用运动组较宣教对照+安慰剂组6分钟步行距离显著改善(平均差+33.6米[95%CI +9.4至+57.7];Hochberg校正P=.02)。
临床怎么用
- 作者结论指出,这些结果证实了运动的益处,但不支持使用GM-CSF治疗外周动脉疾病患者的步行障碍。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking ability in people with lower extremity peripheral artery disease (PAD) are unclear. Walking exercise may augment the effects of GM-CSF in PAD, since exercise-induced ischemia enhances progenitor cell release and may promote progenitor cell homing to ischemic calf muscle. OBJECTIVES: To determine whether GM-CSF combined with supervised treadmill exercise improves 6-minute walk distance, compared with exercise alone and compared with GM-CSF alone; to determine whether GM-CSF alone improves 6-minute walk more than placebo and whether exercise improves 6-minute walk more than an attention control intervention. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial with 2 × 2 factorial design. Participants were identified from the Chicago metropolitan area and randomized between January 6, 2012, and December 22, 2016, to 1 of 4 groups: supervised exercise + GM-CSF (exercise + GM-CSF) (n = 53), supervised exercise + placebo (exercise alone) (n = 53), attention control + GM-CSF (GM-CSF alone) (n = 53), attention control + placebo (n = 51). The final follow-up visit was on August 15, 2017. INTERVENTIONS: Supervised exercise consisted of treadmill exercise 3 times weekly for 6 months. The attention control consisted of weekly educational lectures by clinicians for 6 months. GM-CSF (250 μg/m2/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk for the first 2 weeks of the intervention. MAIN OUTCOMES AND MEASURES: The primary outcome was change in 6-minute walk distance at 12-week follow-up (minimum clinically important difference, 20 m). P values were adjusted based on the Hochberg step-up method. RESULTS: Of 827 persons evaluated, 210 participants with PAD were randomized (mean age, 67.0 [SD, 8.6] years; 141 [67%] black, 82 [39%] women). One hundred ninety-five (93%) completed 12-week follow-up. At 12-week follow-up, exercise + GM-CSF did not significantly improve 6-minute walk distance more than exercise alone (mean difference, -6.3 m [95% CI, -30.2 to +17.6]; P = .61) or more than GM-CSF alone (mean difference, +28.7 m [95% CI, +5.1 to +52.3]; Hochberg-adjusted P = .052). GM-CSF alone did not improve 6-minute walk more than attention control + placebo (mean difference, -1.4 m [95% CI, -25.2 to +22.4]; P = .91). Exercise alone improved 6-minute walk compared with attention control + placebo (mean difference, +33.6 m [95% CI, +9.4 to +57.7]; Hochberg-adjusted P = .02). CONCLUSIONS AND RELEVANCE: Among patients with PAD, supervised treadmill exercise significantly improved 6-minute walk distance compared with attention control + placebo, whereas GM-CSF did not significantly improve walking performance, either when used alone or when combined with supervised treadmill exercise. These results confirm the benefits of exercise but do not support using GM-CSF to treat walking impairment in patients with PAD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01408901.
引用
- McDermott MM, Ferrucci L, Tian L, et al. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. JAMA. 2017. PMID: 29141087. doi:10.1001/jama.2017.17437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。